Baughman Douglas M, Lee Cecilia S, Snydsman Brian E, Jung Hoon C
Department of Ophthalmology, University of Washington, Seattle, Washington, USA.
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
Med Case Rep (Wilmington). 2017;3(2). doi: 10.21767/2471-8041.100044. Epub 2017 Apr 14.
Inflammatory eye disease has been reported as a side effect with Nivolumab.
We report a case of a 92-year-old woman presenting with bilateral and simultaneous keratitis and uveitis in the setting of recurring infusions of nivolumab for metastatic melanoma. The patient underwent successful coordinated treatment of both eyes coinciding with ongoing systemic infusion treatments with ophthalmic topical medications alone.
The interest of this case resides in the simultaneous nature of presentation of eye inflammation both internally and of the ocular surface. Prior case reports have cited uveitis or ocular surface disease, however not in simultaneous fashion. Clinicians should raise their index of suspicion of side effects of nivolumab systemic infusion for any vision or eye symptom changes around the timing of treatment.
有报道称，纳武单抗可引发眼部炎症性疾病。
我们报告一例92岁女性患者，在接受纳武单抗反复输注治疗转移性黑色素瘤期间，出现双侧同时性角膜炎和葡萄膜炎。该患者仅通过眼部局部用药，在进行全身输注治疗的同时成功地对双眼进行了协同治疗。
本病例的关注点在于眼内炎症和眼表炎症同时出现。既往病例报告提及过葡萄膜炎或眼表疾病，但并非同时出现。临床医生应提高对纳武单抗全身输注治疗副作用的怀疑指数，关注治疗期间出现的任何视力或眼部症状变化。
